A novel microsatellite polymorphism in the promoter of human toll-like receptor 2: racial differences, functional implications and possible disease association  by Yim, Jae-Joon et al.
Abstracts of the 12th ISIIH 2S21 
both polymorphisms (-6llA and -56C) was significantly 
higher in DNTM patients than in controls (OR= 16.8, CI 
95%=2.1-132) or in PNTM patients (OR=9.3, CI 
95 % = l.l-78.1).The probability of finding polymorphism 
-6llA in PNTM was higher than in controls (OR=8.4, 
CI 95%=2.4-29.4) but not different than in DNTM 
(OR=1.3, CI 95%=0.1-14). The inferred haplotypes 
also showed a skewed distribution: DNTM vs. controls, 
p=O.Ol; PNTM vs. controls, p=O.O006; and DNTM vs. 
PNTM,p=0.0013. 
1nterpretation:Tbe IFNGRl MPR is highly polymorphic 
and some of these polymorphisms are significantly 
associated with nontuberculous mycobacterial infections. 
This is the first study in which common genetic suscepti- 
bility factors have been associated with both disseminated 
and pulmonary NTM infections. 
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Background:The human toll-like receptor (TLR) family 
plays crucial roles in both the innate and adaptive 
immune systems, Among the 10 TLRs identified, TLR2 
mediates responses to Gram-positive bacteria, including 
mycobacteria. We sought functional polymorphisms in 
the promoter region of TLR2. 
Methods: Using direct sequencing of PCR fragments 
as well as PCR fragment sizing we found a highly 
polymorphic (GT)n dinucleotide repeat around 120 bp 
upstream of the TLR2 translational start site. We 
examined the distribution of each allele in normal donors 
of African (n=106), Caucasian (n=88) and Korean 
(n=98) descent. To further understand the functional 
implications of these polymorphisms, we fused the 1.5 kb 
of upstream TLR2 containing different lengths of GT 
repeat to luciferase and examined these in transient 
transfection under different stimulation conditions. 
Results: The numbers of GT repeats varied from 12 
to 28, with significant differences in allele distribution 
between African Americans and Caucasians (p =0.008) 
and between African Americans and Koreans 
(p=O.O003). The promoter activity of the longer alleles 
[(GT)n 2201 was significantly more inhibited by 200 
IU/ml of interferon-y (p=O.O02) than shorter alleles. 
Interestingly, this inhibition was not observed with 100 
IU/ml of GM-CSF. Genotypes consisting of [(GT)n 
1201 repeats were more prevalent in patients with 
disseminated nontuberculous mycobacterial infection 
(49%) than in normal controls (24%,p=O.O04). 
Interpretation: Given that TLR2 is critical in the human 
immune response against invading organisms, functional 
microsatellite polymorphisms in its promoter may play 
a role in the pathogenesis of infectious and inflammatory 
diseases, This particular TLR2 promoter polymorphism 
is significantly different according to race, appears to 
be disease associated, and is functionally important and 
discriminating in terms of in vitro response to interferon- 
y, a cytokine critical to the integrity of inflammation. 
VIRAL INFECTIONS 
A promising synthetic peptide for the design of an 
Epstein-Barr virus vaccine 
C. Buteau,’ R. Omiya,2 C. Payat E. Celis2 
lDivision of f In ectious Diseases. 2Department of 
Immunology, Mayo Foundation, Rochester, MN USA 
Epstein-Barr virus (EBV) is associated with a deadly 
complication in organ transplantation, the so-called 
posttransplant lymphoproliferative disorders (PTLD). 
Mismatched EBV-seronegative recipients and sero- 
positive donors represent an important risk factor. The 
management of PTLD is difficult and an interesting 
preventive strategy would be to immunize the recipients 
before transplantation.The peptide-based vaccination is 
advantageous because of the absence of genetic material 
and its easiness to be manufactured. Nevertheless human 
leukocyte antigen (HLA) polymorphism in humans is a 
major obstacle to consider. One of the critical aspects to 
design such vaccine is to select a synthetic peptide that 
would be restricted by common HLA alleles and then 
would be available for more individuals such as EBV- 
seronegative ones. 
Objectives: Our main objectives were to evaluate the 
capacity of a synthetic peptide corresponding to EBNA2 
to induce specific T cells in vitro, to determine which 
HLA alleles restricted this epitope, and finally to study 
the reactivity of the specific peptide-induced T cells. 
Methods: We obtained peripheral blood mononuclear 
cells (PBMCs) from ten healthy donors. Then using the 
peptide TVFYNIPPMPL, we induced all these donors to 
select the best responders by proliferation assays. Using 
specific antibodies and HLA-known cells lines, we 
attempted to determine the HLA alleles for this epitope. 
Finally, after positively selected CD4+ cells from the 
best reactive T cell lines, we measured by flowcytometry 
their capacity to inhibit B cell transformation. 
Results: EBV positive serology was confirmed for 6 out 
of the 10 donors. From these latter, 60% shows specific 
T cell response to EBNA2 peptide and these were 
mostly CD4+ T helpers. We found these T cells epitope 
HLA-DR restricted for 5 donors (HLA-DRl: -DR16, - 
